Shawn Singh, Vistagen CEO (Jason Koerner/Getty Images for Concordia Summit)
August 7, 2023 02:26 PM EDT
Pharma

Vista­gen's pos­i­tive PhI­II for so­cial anx­i­ety nasal spray push­es stock price up 1,000+%

Zachary Brennan

Senior Editor

San Fran­cis­co-based Vista­gen saw its stock soar more than 1,000% at one point on Mon­day af­ter un­veil­ing pos­i­tive topline re­sults from a Phase III tri­al …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Lex­i­con ends com­mer­cial work to fo­cus on R&D

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times